New research suggests that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who end conventional lifestyle plans.
Findings released in a prominent health publication points out that while overweight individuals can lose about a fifth of their body weight while on the medication, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying these medications must be cognizant of the danger of quick rebound weight gain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment mass in about one and a half years.
Comparing Approaches
The study, which looked at dozens of trials involving thousands of patients, compared the results of the injectable medications with older methods.
Scientists note that people who lose weight through diet and exercise usually experience a slower creep back—perhaps 0.1 kg a month—post-intervention.
The Reason for the Fast Rebound
Doctors believe the way of the jabs is key to understanding the heightened weight return.
The injections mimic a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement means appetite is uncontrolled, making excessive eating a significant risk."
A Chronic Issue?
The NHS recommend the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts say that, due to the high risk of relapse, the treatment should be considered life-long.
This perspective is echoed by drug manufacturers, who state that the results "underscore the persistent character of excess weight," comparing it to managing conditions like high blood pressure.
User Accounts
Users who have discontinued the jabs report a sudden return of cravings.
"It was like a switch flipping and I was suddenly extremely hungry," said a patient.
The struggle is compounded if users have not developed sustainable lifestyle or habit modifications during treatment.
Significant Adoption
Survey data indicate that millions of adults in the UK have tried these injections in the last 12 months, with desire being substantial.
- Use is more common among women compared to men.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while these medications are potent agents for shedding pounds, they are not a standalone cure and long-term success hinges on ongoing lifestyle support.
